Clinical trials: Prostate Cancer
Metastatic Cancer, Prostate Cancer
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin and leuprolide may fight prostate cancer by stopping the adrenal glands from producing androgens.
- Trial name
- NCT00081159
- Testing
- Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy).
- Trial name
- VAPOR-LTR (NCT07455058)
- Testing
- Vanquish Therapy
- Where
- 4 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Francis Medical Inc.
Prostate Cancer
3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
In standard clinical care, the prostate is imaged by magnetic resonance imaging (MRI) which is a procedure to take pictures of body structures by using a strong magnetic field and radio waves.
- Trial name
- NCT01653093
- Testing
- 3-Tesla magnetic resonance imaging (3T MRI), diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- University of Cincinnati
Prostatic Cancer
Fusion Versus Cognitive MRI Targeted Prostatic Biopsy
The aim of the present study is to compare the accuracy of Magnetic resonance imaging targeted (fusion) versus cognitive prostatic biopsy in biopsy-naïve suspected cancer prostate patient
- Trial name
- NCT05969704
- Testing
- MRI fusion targeted prostatic biopsy, MRI cognitive targeted prostatic biopsy
- Where
- Egypt
- Volunteers
- 130 people
- Sponsor
- Menoufia University
Prostate Cancer Metastatic
Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
This is a Long Term Follow Up study to eRADicAte, an open label study designed to examine the effects of Radium Ra 223 dichloride with concurrent administration of Abiraterone Acetate plus Prednisone Castrate-Resistant…
- Trial name
- Post-eRADicAte (NCT03414437)
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Carolina Research Professionals, LLC
Prostate Cancer
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00026377
- Testing
- bicalutamide, flutamide, goserelin acetate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Prostate Cancer
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer.
- Trial name
- NCT00027599
- Testing
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy
Predicting Operational Difficulties and Outcomes of RARP Based on Preoperative Assessment - Introducing the PIODO Questionnaire
The goal of this observational study is to learn about the factors that affect the course of robot-assisted radical prostatectomy and have an impact on functional and oncological outcomes in patients undergoing RARP.
- Trial name
- NCT06985004
- Testing
- PIODO Questionnaire
- Where
- Poland
- Volunteers
- 288 people
- Sponsor
- Pomeranian Medical University Szczecin
Pain, Prostate Cancer
Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer
RATIONALE: Some drugs used in chemotherapy can reduce the pain experienced by some people with cancer. Combining more than one drug may be more effective at reducing cancer pain.
- Conditions
- Pain, Prostate Cancer, Quality of Life
- Trial name
- NCT00003232
- Testing
- clodronate disodium, mitoxantrone hydrochloride, prednisone
- Where
- 21 sites in Canada
- Volunteers
- 227 people
- Sponsor
- NCIC Clinical Trials Group
Localized T1-T2 Prostate Cancer
SpaceOAR System RWS in China
This study aims to evaluate the safety and performance of SpaceOAR System when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized T1-T2 prostate cancer in China via collecting…
- Trial name
- NCT05407714
- Testing
- SpaceOAR Treatment
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Breast Cancer, Lymphoma
A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle…
- Conditions
- Breast Cancer, Lymphoma, Neoplasm, Prostatic Neoplasm
- Trial name
- NCT00001444
- Testing
- 7-hydroxystaurosporine (UCN-01)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor…
- Trial name
- NCT00217516
- Testing
- selenium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following…
- Trial name
- NCT06813898
- Testing
- Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Patients Scheduled for Prostate Biopsy Because of Increased Serum PSA and/or Abnormal Digital Rectal Examination
Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis
The ultrasound-guided biopsies of the prostate is the validated technique for the diagnosis of prostate cancer, the first human cancer and second leading cause of cancer death.
- Trial name
- NCT01632930
- Testing
- urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)
- Where
- 10 sites in France
- Volunteers
- 962 people
- Sponsor
- Hospices Civils de Lyon
Prostatic Neoplasms, Cancer of the Prostate
Hemi-Ablative Prostate Brachytherapy
This clinical study will evaluate side effects, quality of life and cancer control in patients with prostate cancer diagnosed on only one side of the prostate gland.
- Trial name
- HAPpy (NCT02632669)
- Testing
- Hemigland focal LDR brachytherapy
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
PROSTATE CANCER, Prostate Biopsy
Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection
The goal of this cohort study is to investigate multiparametric ultrasound versus multiparametric MRI for clinically significant prostate cancer detection in patients scheduled for initial biopsy.
- Trial name
- TRUSVSMPMRI (NCT06183905)
- Testing
- Prostate imaging, Prostate biopsy
- Where
- China
- Volunteers
- 635 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer, Sexual Dysfunction
High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate Cancer
RATIONALE: High-intensity focused ultrasound focal ablation uses high-energy sound waves to kill tumor cells. PURPOSE: This phase II trial is studying the side effects of high-intensity focused ultrasound focal ablation and to…
- Trial name
- NCT00988130
- Testing
- laboratory biomarker analysis, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College London Hospitals
Prostate Cancer
Effectiveness of Localized Prostate Cancer Treatments
The purpose of this study is to evaluate the effectiveness of the three most established primary treatments for patients with clinically localized prostate cancer (radical prostatectomy, external-beam radiotherapy, and prostate…
- Trial name
- E-PROSTCaT (NCT01492751)
- Testing
- Quality of life assessment and Clinical evaluation, Radical retropubic prostatectomy surgery, External beam radiotherapy
- Where
- 10 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Fundacion IMIM
Prostate Carcinoma, Recurrent Prostate Carcinoma
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection.
- Trial name
- NCT04857502
- Testing
- 99mTc-based PSMA Imaging and Surgery Agent, Computed Tomography, Single Photon Emission Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Intraprostatic MAXimal Simultaneous Boost
This trial uses a type of radiotherapy called intensity modulated radiotherapy (IMRT), which is able to deliver the radiation to the prostate while delivering less dose to the surrounding normal organs compared with standard 3D…
- Trial name
- NCT00798837
- Testing
- Intraprostatic maximal simultaneous boost
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency